At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 383 enrolled
Drug / intervention
Olopatadine Hydrochloride Ophthalmic Solution 0.2% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparative Study of Olopatadine Hydrochloride Ophthalmic Solution 0.2% QD vs Olopatadine Hydrochloride Ophthalmic Solution 0.1% BID in the Treatment of Allergic Conjunctivitis in Chinese Subjects
In Brief
A Phase 3 clinical trial evaluating Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, and 1 other intervention for Allergic Conjunctivitis. Completed, enrolled 383 participants.
Detailed Summary
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedDec 2014
Primary CompletionOct 2015
TodayJul 2026
First PostedDec 23, 2014
Enrollment StartDec 1, 2014
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.5 years ago
Interventions
Olopatadine Hydrochloride Ophthalmic Solution 0.2%drug
Olopatadine Hydrochloride Ophthalmic Solution 0.1%drug
Olopatadine 0.2% Vehicledrug
Inactive ingredients used as placebo comparator